Last reviewed · How we verify

RNR inhibitor COH29

City of Hope Medical Center · Phase 1 active Small molecule Quality 0/100

RNR inhibitor COH29 is a Small molecule drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: COH29, ribonucleotide reductase holoenzyme inhibitor COH29.

At a glance

Generic nameRNR inhibitor COH29
Also known asCOH29, ribonucleotide reductase holoenzyme inhibitor COH29
SponsorCity of Hope Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RNR inhibitor COH29

What is RNR inhibitor COH29?

RNR inhibitor COH29 is a Small molecule drug developed by City of Hope Medical Center.

Who makes RNR inhibitor COH29?

RNR inhibitor COH29 is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is RNR inhibitor COH29 also known as anything else?

RNR inhibitor COH29 is also known as COH29, ribonucleotide reductase holoenzyme inhibitor COH29.

What development phase is RNR inhibitor COH29 in?

RNR inhibitor COH29 is in Phase 1.

Related